More scrutiny of physician-industry ties
This article was originally published in The Gray Sheet
Medtronic consultant, University of Minnesota professor and spine surgeon David Polly, Jr., M.D., is targeted in an ongoing investigation led by Sen. Chuck Grassley, R-Iowa, into financial ties between medical professionals and device firms. In 2006, Polly lobbied extensively for continued funding of Department of Defense research into combat-related injuries, ultimately receiving DOD funds to head an animal study involving Medtronic's Infuse bone growth morphogenic protein. But in Senate testimony on behalf of the DOD funding, Polly did not disclose his consulting relationship with Medtronic, Grassley charges in a July 24 1letter to Polly's institution. The doctor billed Medtronic more than $50,000 for months of grant lobbying, according to the senator, and received upwards of $1.2 million in consulting fees and expenses from the firm between 2003 and 2007. Grassley sent a separate letter to the National Naval Medical Center on July 29 asking about its policies on physician financial disclosure reporting and conflicts of interest. Grassley sought responses to both letters by Aug. 7
You may also be interested in...
University of Minnesota surgeon David Polly, Jr., M.D., resigns his position on the board of the American Academy of Orthopaedic Surgeons in an Aug. 19 letter. Polly, who had undisclosed consulting ties to Medtronic, is the target of an ongoing investigation by Sen. Chuck Grassley, R-Iowa, into financial ties between medical professionals and device firms (1"The Gray Sheet" Aug. 10, 2009). Polly became an AAOS board member and secretary of AAOS' board of specialty societies in February
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.